MDXG Q2 2021 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+27.1% YoY

Gross Profit

$55M81.3% margin

Operating Income

-$410,000-0.6% margin

Net Income

-$2M-2.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$187M

Total Liabilities

$102M

Stockholders' Equity

$85M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$54M	+27.1%
Gross Profit	$55M	$45M	+21.9%
Operating Income	-$410,000	-$6M	+93.0%
Net Income	-$2M	-$8M	+79.0%

Revenue Segments

Health Care

$59M46%

Advanced Wound Care, Tissue And Other

$53M42%

Section 351

$9M7%

Advanced Wound Care, Umbilical Cord-Derived

$6M5%

Product and Service, Other

$313,0000%